Michael Darmon1,2, Guillaume Thiery3, Magali Ciroldi3, Raphaël Porcher4, Benoît Schlemmer3, Élie Azoulay3. 1. Medical Intensive Care Unit, Saint-Louis University Hospital, Assistance Publique des Hôpitaux de Paris and Paris VII University, 1 av. Claude Vellefaux, 75010, Paris, France. michael.darmon@sls.ap-hop-paris.fr. 2. Medical ICU, Henri Mondor University Hospital, 51 avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France. michael.darmon@sls.ap-hop-paris.fr. 3. Medical Intensive Care Unit, Saint-Louis University Hospital, Assistance Publique des Hôpitaux de Paris and Paris VII University, 1 av. Claude Vellefaux, 75010, Paris, France. 4. Department of Biostatistics, Saint-Louis University Hospital, Assistance Publique des Hôpitaux de Paris and Paris VII University, Paris, France.
Abstract
OBJECTIVES: Cancer patients are at high risk for acute kidney injury (AKI), which is associated with high mortality when renal replacement therapy is required. Because physicians might be reluctant to offer dialysis to patients with malignancies, we sought to appraise outcomes in critically ill cancer patients (mainly with hematological malignancies) who received renal replacement therapy for AKI complicating cancer management. DESIGN: Cohort study including consecutive patients who received renal replacement therapy for AKI complicating cancer management, over a 42-month period. Their mortality was compared with that of non-cancer patients who received renal replacement therapy in the same center over the same study period (control group). SETTING: A 12-bed medical intensive care unit in a university hospital. RESULTS: 94 critically-ill cancer patients met the inclusion criteria. Median SAPS II was 53 (IQR 40-75) and median Logistic Organ Dysfunction score was 7 (IQR 5-10). The etiology of AKI was multiple in most patients (248 identified factors in 93 patients). Hospital mortality was 51.1%. Two variables were independently associated with hospital mortality: the severity of associated organ failures at ICU admission (OR, 1.33; 95% CI, 1.11-1.59; per point) and renal function deterioration after ICU admission (OR, 5.42; 95% CI, 1.62-18.11). Characteristics of the malignancy were not associated with hospital mortality. The presence of cancer had no detectable influence on hospital mortality after adjustment for gender, age, acute severity as assessed by the SAPS II score, and chronic health status [OR 1.2, 95% CI 0.63-2.27; p=0.57]. CONCLUSION: ICU admission should be considered in selected critically ill cancer patients with AKI requiring renal replacement therapy.
OBJECTIVES:Cancerpatients are at high risk for acute kidney injury (AKI), which is associated with high mortality when renal replacement therapy is required. Because physicians might be reluctant to offer dialysis to patients with malignancies, we sought to appraise outcomes in critically ill cancerpatients (mainly with hematological malignancies) who received renal replacement therapy for AKI complicating cancer management. DESIGN: Cohort study including consecutive patients who received renal replacement therapy for AKI complicating cancer management, over a 42-month period. Their mortality was compared with that of non-cancerpatients who received renal replacement therapy in the same center over the same study period (control group). SETTING: A 12-bed medical intensive care unit in a university hospital. RESULTS: 94 critically-ill cancerpatients met the inclusion criteria. Median SAPS II was 53 (IQR 40-75) and median Logistic Organ Dysfunction score was 7 (IQR 5-10). The etiology of AKI was multiple in most patients (248 identified factors in 93 patients). Hospital mortality was 51.1%. Two variables were independently associated with hospital mortality: the severity of associated organ failures at ICU admission (OR, 1.33; 95% CI, 1.11-1.59; per point) and renal function deterioration after ICU admission (OR, 5.42; 95% CI, 1.62-18.11). Characteristics of the malignancy were not associated with hospital mortality. The presence of cancer had no detectable influence on hospital mortality after adjustment for gender, age, acute severity as assessed by the SAPS II score, and chronic health status [OR 1.2, 95% CI 0.63-2.27; p=0.57]. CONCLUSION: ICU admission should be considered in selected critically ill cancerpatients with AKI requiring renal replacement therapy.
Authors: Dominique D Benoit; Pieter O Depuydt; Koenraad H Vandewoude; Fritz C Offner; Tom Boterberg; Carole A De Cock; Lucien A Noens; Ann M Janssens; Johan M Decruyenaere Journal: Intensive Care Med Date: 2005-11-25 Impact factor: 17.440
Authors: Mitchell M Levy; William L Macias; Jean-Louis Vincent; James A Russell; Eliezer Silva; Benjamin Trzaskoma; Mark D Williams Journal: Crit Care Med Date: 2005-10 Impact factor: 7.598
Authors: Márcio Soares; Jorge I F Salluh; Marilia S Carvalho; Michael Darmon; José R Rocco; Nelson Spector Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: E Gruss; C Bernis; J F Tomas; C Garcia-Canton; A Figuera; J L Motellón; V Paraiso; J A Traver; J M Fernandez-Rañada Journal: Am J Nephrol Date: 1995 Impact factor: 3.754
Authors: Sean M Bagshaw; Kevin B Laupland; Christopher J Doig; Garth Mortis; Gordon H Fick; Melissa Mucenski; Tomas Godinez-Luna; Lawrence W Svenson; Tom Rosenal Journal: Crit Care Date: 2005-10-25 Impact factor: 9.097
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-02-29 Impact factor: 17.440
Authors: Abhijat Kitchlu; Eric McArthur; Eitan Amir; Christopher M Booth; Rinku Sutradhar; Habeeb Majeed; Danielle M Nash; Samuel A Silver; Amit X Garg; Christopher T Chan; S Joseph Kim; Ron Wald Journal: J Natl Cancer Inst Date: 2019-07-01 Impact factor: 13.506
Authors: Harish Seethapathy; Meghan D Lee; Ian A Strohbehn; Orhan Efe; Nifasha Rusibamayila; Donald F Chute; Robert B Colvin; Ivy A Rosales; Riley M Fadden; Kerry L Reynolds; Ryan J Sullivan; Howard L Kaufman; Kenar D Jhaveri; Meghan E Sise Journal: Nephrol Dial Transplant Date: 2022-02-25 Impact factor: 5.992